Pharma firms AstraZeneca and Daiichi Sankyo are betting on a new class of cancer drug known as antibody–drug conjugates or ADCs – and the firms are coming up trumps. In January, the partners’ drug Enhertu (trastuzumab deruxtecan) was approved by US regulators for HER2-positive gastric ca...
Like BsAb, antibody-drug conjugate (ADC) is another hot modality in recent business deals. The ADC sales are expected to reach $16.4 billion in 2026 (7). Although the number of ADC deals is low in our covered period (only 1 out of 19), domestic ADC development is making significantprogr...
The emerging novel drug modality of degrader-antibody conjugates represents the convergence of the existing technologies of antibody-drug conjugation and targeted protein degradation with the goal of combining the str...
ADC: antibody-drug conjugates; ISAC: immune-stimulating antibody conjugates; sdAb: single-domain antibodies Immune Checkpoint Blockade Deals The licensing deals were dominated by naked monoclonal antibodies (mAb) with a total value ...
· Tristan Manalac Funding Seaport, Six Months Out of Stealth, Comes Back for $225M Raise October 21, 2024 · 1 min read · Annalee Armstrong Deals Sanofi Seals Deal With Private Equity Firm for 50% Stake in Consumer Health...
Class Antineoplastics; Drug conjugates; Immunoconjugates; Macrolides; Monoclonal antibodies Mechanism of Action Apoptosis stimulants; Epidermal growth factor inhibitors; Mitosis inhibitors Orphan Drug Status Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for ra...
In December 2022, Merck KGaA collaborated with Kelun-Biotech to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer. Northbrook, IL 60062 -- (SBWIRE) -- 03/20/2023 --Custom Antibody Marketworth $860 million by 20...
ClassImmunoconjugates; Monoclonal antibodies Mechanism of ActionAntibody-dependent cell cytotoxicity Orphan Drug Status Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. No New Molecular EntityYes ...
Amber Tong Seagen, whose suite of antibody-drug conjugates enticed Pfizer to a $43 billion buyout, is looking to put a twist on the idea. The Seattle-based drugmaker … Sign up to read this article for free. ...
AMSTERDAM,SAN FRANCISCO,HOUSTONandSINGAPORE,Jan. 4, 2023/PRNewswire/ -- Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs...